TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to help enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. These products target large, underserved, and growing markets in women's healthcare. The company also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands.
Company Growth (employees)
Boca Raton, US
Size (employees)
159 (est)+31%
TherapeuticsMD was founded in 2008 and is headquartered in Boca Raton, US

Key People at TherapeuticsMD

Robert Finizio

Robert Finizio

Chief Executive Officer
Dan Cartwright

Dan Cartwright

Chief Financial Officer
John Milligan

John Milligan

Julia Amadio

Julia Amadio

Chief Product Officer
Brian Bernick

Brian Bernick

MD, Chief Medical Officer
Mitchell Krassan

Mitchell Krassan

Chief Strategy Performance Officer

TherapeuticsMD Office Locations

TherapeuticsMD has an office in Boca Raton
Boca Raton, US (HQ)
6800 Broken Sound Pkwy Nw

TherapeuticsMD Data and Metrics

TherapeuticsMD Financial Metrics

TherapeuticsMD's revenue was reported to be $19.4 m in FY, 2016 which is a 4% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

19.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.2 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(89.9 m)

EBIT (FY, 2016)

(90.3 m)

Market capitalization (26-May-2017)

811.6 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

131.5 m
TherapeuticsMD's current market capitalization is $811.6 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


8.8 m15 m20.1 m19.4 m

Revenue growth, %


Cost of goods sold

2 m3.7 m4.5 m4.2 m

Gross profit

6.8 m11.4 m15.6 m15.2 m

Gross profit Margin, %


Operating expense total

32.6 m65.4 m100.8 m105.4 m


(25.8 m)(54 m)(85.2 m)(90.3 m)

EBIT margin, %


Interest expense

1.2 m1.2 m

Interest income

27.2 k37.3 k17.4 k

Pre tax profit

(85.1 m)(89.9 m)

Net Income

(28.4 m)(54.2 m)(85.1 m)(89.9 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


54.2 m51.4 m64.7 m131.5 m

Accounts Receivable


1 m1.2 m690.2 k1.1 m

Current Assets

59.4 m56.2 m70.7 m139.4 m

Total Assets

62 m59.1 m73.7 m142.5 m

Accounts Payable

2.1 m6.3 m3.1 m7.4 m

Current Liabilities

7.3 m10.7 m10.7 m15 m

Non-Current Liabilities

Additional Paid-in Capital

135.1 m183 m282.7 m437 m

Retained Earnings

(80.5 m)(134.7 m)(219.8 m)(309.7 m)

Total Equity

54.7 m48.4 m63.1 m127.5 m

Financial Leverage

1.1 x1.2 x1.2 x1.1 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.4 m)(54.2 m)(85.1 m)(89.9 m)

Depreciation and Amortization

58.1 k52.5 k62.4 k132.5 k

Accounts Receivable

(1.1 m)(458 k)(917.7 k)(4 m)


571.6 k(138.5 k)492 k(386.2 k)

Accounts Payable

472.9 k4.2 m(3.2 m)4.2 m

Cash From Operating Activities

52.6 m(2.8 m)13.3 m(69.1 m)

Purchases of PP&E

(40.8 k)(31 k)(165.3 k)(396.2 k)

Cash From Investing Activities

(583.6 k)(606.8 k)(584.4 k)(1.3 m)

Cash From Financing Activities

137.2 m

Interest Paid

212.9 k212.9 k212.9 k
Y, 2016

Financial Leverage

1.1 x

TherapeuticsMD Market Value History

TherapeuticsMD Online and Social Media Presence

TherapeuticsMD Company Life and Culture

You may also be interested in